A Study of BCMA CAR-T Cells for Patients With Relapse and Refractory Multiple Myeloma

Trial Profile

A Study of BCMA CAR-T Cells for Patients With Relapse and Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs B-cell maturation antigen CAR-T cell therapy - Pregen ShenZhen Biotechnology (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top